Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.

摘要: Delafloxacin has recently received approval by the US Food and Drug Administration for treatment of acute bacterial skin structure infections. This article provides a balanced comprehensive systematic critique literature in order to provide an up-to-date summary its clinical pharmacology. Oral delafloxacin is rapidly absorbed exhibits comparable exposure characteristics (300 mg intravenous versus 450 mg oral) between two formulations, allowing easy transition from oral therapy. The bioavailability high (60–70%) absorption not affected food intake, although further studies are required under clinically relevant conditions. primarily excreted renally (thus requiring renal dose adjustment setting dysfunction), but also undergoes metabolism uridine diphosphate-glucuronosyltransferase enzymes formation conjugated metabolite. Few drug-drug interaction have been identified, more characterizations vitro vivo warranted. concentration-dependent bactericidal agent that susceptibility gram-positive (notably potent activity against methicillin-resistant Staphylococcus aureus), gram-negative, anaerobic organisms. In addition infections, utility studied community-acquired pneumonia, exacerbation chronic bronchitis, gonorrhea, with potentially promising findings. Given mild side effect profile, including apparent lack association important QTc prolongation, generally well tolerated.